8 Amendments of Demetris PAPADAKIS related to 2016/2057(INI)
Amendment 10 #
Draft opinion
Paragraph 1 a (new)
Paragraph 1 a (new)
1a. Recognises that the case of the highly priced medicine "sovaldi" for the treatment of hepatitis C has been a determining factor for giving serious consideration to the real difficulty to guarantee access to medicines around the world even in developed countries. In particular medicines to treat rare and oncological diseases;
Amendment 17 #
Draft opinion
Paragraph 2 a (new)
Paragraph 2 a (new)
2a. Recalls that article 168/4 of the TFEU provides the EU with competences to guarantee that the authorisation of medicines shall ensure high standards of quality, safety and effectiveness. Considers that the European Commission shall develop the principles of safety and efficiency to improve access to high quality medicines in a safe and equitable way;
Amendment 24 #
Draft opinion
Paragraph 3
Paragraph 3
3. Deplores the fact that there are 18 million people without access to health care or medicines, whose human rights are being violated on a daily basis; finds it alarming that there are 25 000 annual deaths in the EU due to lack of effective antibiotics, vaccines and treatments for rare diseases. Calls for a rethink of (to re- set) research priorities in order to respond to all health challenges. Calls for a review of the incentives put in place to encourage research on "orphan medicines" to see if they are successful, otherwise calls for new incentives;
Amendment 34 #
Draft opinion
Paragraph 4
Paragraph 4
4. Recognises as key obstacles to access to medicines the lack of affordability and availability of medicines, the budgetary cuts resulting from the financial crisis, the high price of medicines and the monopolies of large companies in the marketshortage of medicines and the lack of research on certain diseases;
Amendment 60 #
Draft opinion
Paragraph 7
Paragraph 7
7. Identifies patent rights as a major obstacRecognises the need to review patenting rules to improve access to medicines and incentivise research, and urges public policy makers to take proactive steps towards making generic and biosimilar medicines available, always taking into account the need to ensure the same beneficial effects, continuity of patient care and prevention of any risk of abuse or misuse of the regulatory framework;
Amendment 70 #
Draft opinion
Paragraph 8 – subparagraph 1 (new)
Paragraph 8 – subparagraph 1 (new)
Underlines the importance of information-sharing and cooperation between Member States on pricing, reimbursement and procurement policies, as well as cooperation between stakeholders in order to facilitate better balancing of the value of innovation with equitable, affordable patient access.
Amendment 82 #
Draft opinion
Paragraph 9
Paragraph 9
9. Underlines that free trade agreements such as TTIP and TiSA may seriously damage Member States’ healthcare systems, paving the way for wider liberalisation and privatisation in vital sectors and further undermining the principle of universal access to healthcarethe report refers to the medicine policy in the EU, but must ensure that future international trade agreements do not undermine access to medicines;
Amendment 94 #
Draft opinion
Paragraph 10 a (new)
Paragraph 10 a (new)
10a. Calls on the Commission, in close cooperation with the Member States, to promote information-sharing, participation and coordination in medicine policy, in particular on pricing, reimbursement and procurement policies.